| 3856- | CUR, | Curcumin induces IL-6 receptor shedding via the ADAM10 proteinase |
| - | in-vitro, | AD, | NA |
| 3797- | CUR, | Curcumin reverses cognitive deficits through promoting neurogenesis and synapse plasticity via the upregulation of PSD95 and BDNF in mice |
| - | in-vitro, | NA, | NA |
| 3862- | CUR, | RES, | The metalloproteinase ADAM10: A useful therapeutic target? |
| - | Review, | AD, | NA |
| 3857- | CUR, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 3583- | CUR, | Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers |
| - | Review, | Arthritis, | NA |
| 3590- | CUR, | The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern? |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3586- | CUR, | PI, | Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers |
| - | in-vivo, | NA, | NA |
| 3585- | CUR, | Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer |
| - | Study, | NA, | NA |
| 3584- | CUR, | Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids |
| 3582- | CUR, | PI, | Therapeutic and Preventive Effects of Piperine and its Combination with Curcumin as a Bioenhancer Against Aluminum-Induced Damage in the Astrocyte Cells |
| 3581- | CUR, | Curcumin Attenuated Neurotoxicity in Sporadic Animal Model of Alzheimer's Disease |
| - | NA, | AD, | NA |
| 3580- | CUR, | Curcumin Acts as Post-protective Effects on Rat Hippocampal Synaptosomes in a Neuronal Model of Aluminum-Induced Toxicity |
| - | in-vivo, | AD, | NA |
| 3579- | CUR, | AgNPs, | Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin |
| - | Review, | NA, | NA |
| 3578- | CUR, | SIL, | Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation |
| - | in-vitro, | CRC, | DLD1 |
| 3577- | CUR, | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study |
| - | Trial, | AD, | NA |
| 3576- | CUR, | Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3575- | CUR, | The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse |
| - | in-vivo, | AD, | NA |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| - | Analysis, | GBM, | NA |
| 4333- | Cyste, | Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription |
| - | vitro+vivo, | AD, | NA |
| 4332- | Cyste, | Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases |
| - | in-vivo, | Park, | NA | - | in-vivo, | HD, | NA |
| 4331- | Cyste, | Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase |
| - | in-vivo, | HD, | NA | - | NA, | AD, | NA |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1877- | DCA, | Non-Hodgkin′s Lymphoma Reversal with Dichloroacetate |
| - | Case Report, | lymphoma, | NA |
| 1874- | DCA, | Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | MDAH-2774 |
| 1876- | DCA, | Chemo, | In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines |
| - | in-vivo, | Lung, | H727 |
| 1875- | DCA, | Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells |
| - | in-vitro, | neuroblastoma, | NA | - | in-vivo, | NA, | NA |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 1879- | DCA, | Long-term stabilization of metastatic melanoma with sodium dichloroacetate |
| - | Case Report, | Melanoma, | NA |
| 1880- | DCA, | A Novel Form of Dichloroacetate Therapy for Patients With Advanced Cancer: A Report of 3 Cases |
| - | Case Report, | Var, | NA |
| 1881- | DCA, | Chemo, | Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report |
| - | in-vitro, | NA, | HT1080 | - | in-vitro, | NA, | WI38 | - | Case Report, | Var, | NA |
| 1882- | DCA, | Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer |
| - | Analysis, | NA, | NA |
| 1883- | DCA, | In vivo metabolic response of glucose to dichloroacetate in humans |
| - | Analysis, | Var, | NA |
| 1884- | DCA, | Sal, | Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1872- | DCA, | Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment |
| - | in-vitro, | Oral, | HSC2 | - | in-vitro, | Oral, | HSC3 |
| 1870- | DCA, | Rad, | Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation |
| - | in-vitro, | Pca, | PC3 |
| 1869- | DCA, | Dichloroacetate induces autophagy in colorectal cancer cells and tumours |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HT-29 |
| 1868- | DCA, | MET, | Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy |
| - | Case Report, | NA, | NA |
| 1867- | DCA, | Chemo, | Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | NA |
| 1866- | DCA, | MET, | BTZ, | Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner |
| - | in-vivo, | NA, | NA |
| 1865- | DCA, | Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 1887- | DCA, | GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate |
| - | in-vitro, | Var, | NA |
| 1889- | DCA, | A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth |
| - | Review, | Var, | NA |
| 1885- | DCA, | Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 4901- | DCA, | Sal, | Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer |
| - | Review, | NSCLC, | NA |
| 5194- | DCA, | Metabolic modulation of glioblastoma with dichloroacetate |
| - | vitro+vivo, | GBM, | NA |
| 5195- | DCA, | Rad, | Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | EMT6 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid